Sumant Rawat
Pueblo, CONPI 1710930672
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 95.0% of the total across 263 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 41 manufacturers, the largest accounting for just 11.7% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $1,539 and has fallen 72.8% since, to $419 in 2022.
Across 263 payments — averaging $17.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$553
- AbbVie$465
- Biogen$359
- MDD US Operations, LLC$229
- Teva Pharmaceuticals USA, Inc.$220
- Sanofi$217
- plus $3K from 35 others
What the payments were for
- Speaking & faculty fees$1363%
- Food & beverage$4,49495%
- Education$1022%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Zonisamide | 14 | $97 |
Paid to pharmacies, not to this prescriber.
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.